AstraZeneca reported strong results in Q4, although partly driven by one-offs. The oncology business has become heavy in terms of potential, following the launches last year. This has raised our confidence of the company’s ability to repeat this performance in the commercial delivery of these drugs.
09 Feb 2018
Upgrade on the back of improvement in R&D delivery
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Upgrade on the back of improvement in R&D delivery
AstraZeneca PLC (AZN:LON) | 10,706 -3640 (-0.3%) | Mkt Cap: 165,965m
- Published:
09 Feb 2018 -
Author:
Kamla Singh -
Pages:
3
AstraZeneca reported strong results in Q4, although partly driven by one-offs. The oncology business has become heavy in terms of potential, following the launches last year. This has raised our confidence of the company’s ability to repeat this performance in the commercial delivery of these drugs.